Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic.

Huskamp, Haiden A; Busch, Alisa B; Uscher-Pines, Lori; Barnett, Michael L; Riedel, Lauren; Mehrotra, Ateev

Huskamp, Haiden A; Busch, Alisa B; Uscher-Pines, Lori; Barnett, Michael L; Riedel, Lauren; Mehrotra, Ateev.

Huskamp HA; Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
Busch AB; McLean Hospital, Belmont, Massachusetts.
Uscher-Pines L; RAND Corporation, Arlington, Virginia.
Barnett ML; Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Riedel L; Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
Mehrotra A; Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

JAMA ; 324(23): 2440-2442, 2020 12 15.

Article in English | MEDLINE | ID: covidwho-1064274

Subject(s)

Buprenorphine/therapeutic use; COVID-19; Drug Prescriptions/statistics & numerical data; Narcotic Antagonists/therapeutic use; Opioid-Related Disorders/drug therapy; Pandemics; Adolescent; Adult; Drug Utilization/trends; Female; Humans; Insurance Coverage; Male; Medicare; Middle Aged; United States; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Prescriptions / Buprenorphine / Pandemics / COVID-19 / Narcotic Antagonists / Opioid-Related Disorders Limits: Adolescent / Adult / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: North America Language: English Journal: JAMA Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google